Summary

Pulmonary Arterial Hypertension Market Growth & Trends

The global pulmonary arterial hypertension market size is expected to reach USD 7.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.9% from 2021 to 2028. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs are fueling the market growth.

The COVID-19 pandemic did not have much impact on the PAH market due to the normal demand for PAH drugs by the patients. All the market players reported positive growth rates in their year-on-year revenues from 2019 to 2020. However, the supply chains were disrupted to a certain level due to lockdowns in many nations globally. Overall, the impact was neutralized due to the continuous demand for drugs.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of this disorder is intensifying due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions.

The existence of a large geriatric population having lower levels of immunity is prone to PAH and associated diseases is a high impact-rendering factor for the growth of the PAH market over the forecast period. Though the beginning age for PAH is 45 years, it is often observed to occur in a population over 60 years of age.

Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth. These are the two most vital acts that promote the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders and has a smaller market share.

Robust drug pipeline and new product combination awaiting approval or launch are anticipated to heighten the market competitiveness over the forecast period. In December 2020, Acceleron Pharma received orphan drug designation for Sotatercept from the European Commission and is available for commercial use in the European markets.

Pulmonary Arterial Hypertension Market Report Highlights

• By drug class, prostacyclin and prostacyclin analogs are projected to witness lucrative growth over the forecast period. The sales of these drugs are anticipated to grow sharply in the future, primarily due to the growth expected in oral prostacyclin agents

• North America dominated the PAH market with over 55.0% share in 2020. This is attributed to its supportive infrastructure for the development and distribution of high-quality therapies. In addition, the availability of reimbursement on PAH therapies support the market growth

• Asia Pacific is anticipated to expand at the fastest CAGR of 5.9% over the forecast period due to its large population base, rapid economic developments, and improving healthcare systems. Besides, the high burden of diseases such as HIV, which are responsible for the development of PAH, foster the growth of this regional market

• The market is consolidated and competitive. Players enjoy the benefit of high entry barriers to other firms due to the high price interdependency

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Drug class
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Market Formulation & Validation
1.4.2 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.7.1 Commodity Flow Analysis (Model 1)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
2.2 Patent Expiration
Chapter 3 PAH Market Variables, Trends and Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market
3.1.2 Ancillary Market
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, By Stage
3.3.1 Early Phase I and Phase I
3.3.2 Phase II
3.3.3 Phase III
3.3.4 Phase IV
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List of Key End Users
3.6 List of Generic Drugs
3.7 Regulatory Framework
3.7.1 Reimbursement framework
3.7.1.1 Therapy cost
3.7.1.2 Therapy monitoring cost
3.7.1.3 Average Selling Price
3.7.2 Standards & compliances
3.8 Market Variable Analysis
3.8.1 Market Driver Analysis
3.8.1.1 Incidents of Pulmonary Arterial Hypertension (PAH)
3.8.1.2 Growing Geriatric Population
3.8.1.2.1 Global Geriatric Population
3.8.1.2.2 U.S. Geriatric Population
3.8.1.2.3 Canada Geriatric Population
3.8.1.3 Government Support for Development of Orphan Drugs
3.8.2 Market Restraint Analysis
3.8.2.1 Patent Expiration of Key Molecules
3.8.3 Industry Challenges
3.8.3.1 High cost of drug development
3.9 Pulmonary Arterial Hypertension Market: Analysis Tools
3.9.1 Porter’s Five Forces Analysis
3.9.1.1 Supplier Power: Low
3.9.1.2 Buyer Power: moderate
3.9.1.3 Substitution Threat: moderate
3.9.1.4 Threat from new entrant: moderate
3.9.1.5 Competitive rivalry: high
3.9.2 PESTEL Analysis
3.10 Major Deals & Strategic Alliances Analysis
3.10.1 Product Development
3.10.2 Mergers & Acquisitions
3.10.3 Product Promotion Strategies
3.11 Market Entry Strategies
3.12 Disease Prevalence Analysis
3.12.1 U.S.
3.12.2 Canada
3.12.3 Europe
3.12.4 U.K.
3.12.5 Germany
3.12.6 France
3.12.7 Italy
3.12.8 Spain
3.12.9 Scotland
3.12.10 Belgium
3.12.11 Japan
3.12.12 Australia
3.12.13 South Korea
3.12.14 LATAM
Chapter 4 PAH Market: Impact of COVID-19
4.1 Current and Future Impact Analysis
4.2 Impact on Market Players
4.3 Opportunity Analysis
Chapter 5 PAH Market: Segment Market Analysis, By Drug Class, 2016 - 2028 (USD Million)
5.1 PAH market: share analysis, 2020 & 2028
5.2 PAH market: share analysis, 2020 & 2028
5.3 Prostacyclin And Prostacyclin Analogs
5.3.1 Prostacyclin and Prostacyclin Analogs market, 2016 - 2028 (USD Million)
5.4 Soluble Guanylate Cyclase (SGC) Stimulators
5.4.1 SGC stimulators market, 2016 - 2028 (USD Million)
5.5 Endothelin Receptor Antagonist (ERA)
5.5.1 ERA market, 2016 - 2028 (USD Million)
5.6 Phosphodiesterase 5 (PDE-5)
5.6.1 PDE-5 market, 2016 - 2028 (USD Million)
Chapter 6 PAH Market: Regional Market Analysis, By Drug Class, 2016 - 2028 (USD Million)
6.1 Definition & Scope
6.1.1 PAH market, by Regions, 2016 - 2028 (USD Million)
6.2 PAH Market Shares By Region, 2020 & 2028
6.3 North America
6.3.1 North America PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.3.2 U.S.
6.3.2.1 U.S. PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.3.3 Canada
6.3.3.1 Canada PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4 EUROPE
6.4.1 Europe PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4.2 U.K.
6.4.2.1 U.K. PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4.3 Germany
6.4.3.1 Germany PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4.4 France
6.4.4.1 France PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4.5 Italy
6.4.5.1 Italy PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.4.6 Spain
6.4.6.1 Spain PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.5 Asia Pacific
6.7.1 Asia Pacific PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.2 Japan
6.7.3 Japan PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.4 China
6.7.4.1 China PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.5 India
6.7.5.1 India PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.6 South Korea
6.7.6.1 South Korea PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.7 Australia
6.7.7.1 Australia PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.6 Latin America
6.7.1 Latin America PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.2 Brazil
6.7.2.1 Brazil PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.3 Mexico
6.7.3.1 Mexico PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.4 Argentina
6.7.4.1 Argentina PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7 MEA
6.7.1 MEA PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.2 South Africa
6.7.2.1 South Africa PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.3 Saudi Arabia
6.7.3.1 Saudi Arabia PAH market estimates and forecasts, 2016 - 2028 (USD Million)
6.7.4 UAE
6.7.4.1 UAE PAH market estimates and forecasts, 2016 - 2028 (USD Million)
Chapter 7 PAH Market - Competitive Analysis
7.1 Company Profiles
7.1.1 Johnson & Johnson Services, Inc.
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 Gilead Sciences, Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 United Therapeutics Corporation
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Acceleron Pharma, Inc.
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 GlaxoSmithKline Plc. (GSK)
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Pfizer, Inc.
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.7 Bayer AG
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.2 KOL COMMENTARY


List of Tables

Table 1 Primary interview details: North America
Table 2 Primary interview details: Europe
Table 3 Primary interview details: Asia Pacific
Table 4 Primary interview details: Latin America
Table 5 Primary interview details: Middle East and Africa
Table 6 List of secondary sources
Table 7 List of key companies
Table 8 Summary of pipeline analysis for Early Phase I & Phase I PAH Agents
Table 9 Summary of pipeline analysis for Phase II PAH Agents
Table 10 Summary of pipeline analysis for Phase III PAH Agents
Table 11 Summary of pipeline analysis for Phase IV Agents
Table 12 Monthly therapy cost for PAH Agents
Table 13 Payer specific per patient per year monitoring cost by medication class
Table 14 Average selling prices for approved PAH agents in the U.S. (2020)
Table 15 North America Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 16 North America Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (Million Units)
Table 17 U.S. Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 18 Canada Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 19 Europe Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 20 Europe Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (Million Units)
Table 21 U.K. Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 22 Germany Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 23 France Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 24 Italy Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 25 Spain Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 26 Asia Pacific Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 27 Asia Pacific Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (Million Units)
Table 28 Japan Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 29 South Korea Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 30 China Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 31 India Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 32 Australia Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 33 Latin America Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 34 Brazil Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 35 Mexico Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 36 Argentina Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 37 MEA Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 38 MEA Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (Million Units)
Table 39 South Africa Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 40 UAE Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)
Table 41 KSA Pulmonary Arterial Hypertension market, by drug class, 2016 - 2028 (USD Million)

List of Figures

Fig. 1 PAH market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Commodity flow analysis
Fig. 11 Market snapshot, 2020 (USD Million)
Fig. 12 Patent term expiry of the key PAH brands
Fig. 13 Ancillary market analysis
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Consumer behavior analysis
Fig. 16 Market influencer analysis
Fig. 17 Market variables
Fig. 18 Market driver analysis
Fig. 19 Global prevalence of PAH
Fig. 20 Global geriatric population, 2010 - 2050 (Million)
Fig. 21 Market restraint analysis
Fig. 22 Porters Analysis
Fig. 23 PESEL
Fig. 24 Strategy mapping
Fig. 25 Market entry strategies
Fig. 26 PAH market: Drug class dashboard
Fig. 27 PAH market: Drug class movement analysis
Fig. 28 Prostacyclin pathway
Fig. 29 Prostacyclin and prostacyclin analogs market, 2016 - 2028 (USD Million)
Fig. 30 Nitric oxide pathway
Fig. 31 SGC stimulators market, 2016 - 2028 (USD Million)
Fig. 32 Endothelial pathway
Fig. 33 ERA market, 2016 - 2028 (USD Million)
Fig. 34 PDE-5 market, 2016 - 2028 (USD Million)
Fig. 35 PAH market, by regions, 2016 - 2028 (USD Million)
Fig. 36 Regional marketplace: Key takeaways
Fig. 37 Regional outlook, 2020 & 2028
Fig. 38 North America PAH market, 2016 - 2028(USD Million)
Fig. 39 U.S. PAH market, 2016 - 2028(USD Million)
Fig. 40 Canada PAH market, 2016 - 2028(USD Million)
Fig. 41 Europe PAH market, 2016 - 2028(USD Million)
Fig. 42 U.K. PAH market, 2016 - 2028(USD Million)
Fig. 43 Germany PAH market, 2016 - 2028(USD Million)
Fig. 44 France PAH market, 2016 - 2028 (USD Million)
Fig. 45 Italy PAH market, 2016 - 2028 (USD Million)
Fig. 46 Spain PAH market, 2016- 2028 (USD Million)
Fig. 47 Asia Pacific PAH market, 2016 - 2028 (USD Million)
Fig. 48 Japan PAH market, 2016 - 2028 (USD Million)
Fig. 49 China PAH market, 2016 - 2028 (USD Million)
Fig. 50 India PAH market, 2016 - 2028 (USD Million)
Fig. 51 South Korea PAH market, 2016- 2028 (USD Million)
Fig. 52 Australia PAH market, 2016 - 2028 (USD Million)
Fig. 53 Latin America PAH market, 2016 - 2028 (USD Million)
Fig. 54 Brazil PAH market, 2016 - 2086 (USD Million)
Fig. 55 Mexico PAH market, 2016 - 2028 (USD Million)
Fig. 56 Argentina PAH market, 2016 - 2028 (USD Million)
Fig. 57 MEA PAH market, 2016 - 2028 (USD Million)
Fig. 58 South Africa PAH market, 2016 - 2028 (USD Million)
Fig. 59 Saudi Arabia PAH market, 2016 - 2028 (USD Million)
Fig. 60 UAE PAH market, 2016 - 2028 (USD Million)
Fig. 61 KOL Commentary